Breakthrough Discovery: Cannabis Compounds Show Promise in Treating Fatty Liver Disease
A groundbreaking study by researchers at the Hebrew University of Jerusalem has revealed that two non-psychoactive compounds found in the cannabis plant, CBD and CBG, may hold the key to treating fatty liver disease, the world’s most common chronic liver disorder. The study, published in the British Journal of Pharmacology, found that these compounds can significantly reduce liver fat and improve metabolic health.
The research team, led by Prof. Joseph Tam, Dr. Liad Hinden, and Ph.D. student Radka Kočvarová, discovered that CBD and CBG work by creating a backup energy reserve in the liver and restoring the activity of cellular “cleaning crews” to break down harmful waste. This breakthrough highlights a new, plant-based approach to treating fatty liver disease, which affects millions of people worldwide.
The study’s findings suggest that CBD and CBG can improve liver health by altering the organ’s energy management and cleaning processes. These non-psychoactive compounds do not cause a high, making them a promising treatment option for patients seeking alternative therapies.
This research has significant implications for the treatment of fatty liver disease, a condition that is often linked to obesity, diabetes, and other metabolic disorders. The discovery of CBD and CBG’s potential therapeutic benefits may lead to new avenues for treatment and improved patient outcomes.
